LeMaitre Vascular stock (US52567J1079): Insiders sell amid recent price drop

LeMaitre Vascular stock experienced a notable decline, dropping 5.8% to $101.64 on May 11, 2026, amid heavier-than-normal trading volume, according to MarketBeat as of 05/11/2026. Insider transactions included sales by Trent Kamke (2,928 shares) and Bridget Ross (5,044 shares) on May 11, while CEO George W. LeMaitre sold 46,481 shares on May 7-8 at around $108 per share, per SEC filings and MarketBeat as of 05/11/2026. This comes after Q1 results with EPS of $0.68 beating estimates and revenue up 11.1% to $66.55 million year-over-year.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

LeMaitre Vascular: core business model

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices for peripheral vascular disease treatment. The company's portfolio includes vascular grafts, patches, surgical instruments, catheters, and embolic protection devices, serving surgeons treating conditions like aneurysms and blockages, according to company descriptions in MarketBeat as of 05/11/2026.

Headquartered in Burlington, Massachusetts, LeMaitre Vascular focuses on niche products for vascular surgery, with a strong emphasis on innovation in disposable and implantable devices. This model targets the growing demand for minimally invasive vascular procedures in the US healthcare market.

Main revenue and product drivers for LeMaitre Vascular

Key products drive revenue through surgical consumables and biologics. Recent Q1 2026 results showed revenue of $66.55 million, up 11.1% year-over-year, with EPS of $0.68 exceeding estimates, per MarketBeat as of 05/11/2026. The company also declared a quarterly dividend of $0.25 per share.

Revenue is primarily from the US market, bolstered by products like the AnastoClip, XenoSure biologic patch, and embolectomy catheters, which benefit from recurring hospital purchases and expanding vascular procedures among aging US populations.

Industry trends and competitive position

The peripheral vascular device market benefits from rising cardiovascular disease prevalence in the US, with aging demographics driving procedure volumes. LeMaitre Vascular holds a specialized niche against larger peers like Medtronic or Boston Scientific, focusing on surgeon-preferred tools with high margins from proprietary tech.

Why LeMaitre Vascular matters for US investors

As a Nasdaq-listed medtech firm based in Massachusetts, LeMaitre Vascular offers US investors exposure to the domestic healthcare sector, which comprises over 40% of global medtech spending. Its products support critical US hospital networks, tying performance to Medicare reimbursement trends and elective surgery recovery.

Conclusion

LeMaitre Vascular reported solid Q1 results with revenue growth and a dividend, yet faced a share price drop amid insider selling on May 11, 2026. Analyst consensus remains Moderate Buy with a $112.60 target, reflecting optimism despite recent transactions. Investors track upcoming catalysts like further earnings and market dynamics in vascular medtech.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.